Home › Research › Drug development
Reversibility and Access: A Two-Axis Framework for Glucagon-Like Peptide-1 Receptor Agonists Across the Neurological Spectrum, and a Falsifiable Analgesic Hypothesis for Chronic Migraine
Sulter GA.. Preprints.org, 2026-07-17
Topic: Gut, metabolism and diet
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have moved rapidly from metabolic medicine into neurology, but the evidence to mid-2026 refuses to resolve into a single narrative of neuroprotection. Large cardiovascular outcome trials establish these drugs for ischaemic stroke prevention, whereas rigorous phase 3 trials in Parkinson's disease and Alzheimer's disease found no effect on clinical progression despite favourable cerebrospinal fluid biomarker shifts. I argue that this pattern is not contradictory but structured by two axes. The first is tissue reversibility, which determines whether disease modification is possible at all: a remodellable vascular substrate responds, an autonomously degenerating parenchyma does not, and a functionally disordered but structurally intact network should. The second is molecular access, which determines which agent can work, and it inverts across indications: long-acting human analogues reduce stroke risk while short-acting exendins do not, yet exenatide lowers intracranial pressure in idiopathic intracranial hypertension because the choroid plexus lies outside the blood-brain barrier. Chronic migraine occupies the reversible, extra-barrier quadrant. Recent receptor-level work shows GLP-1-derived peptides inhibit TRPV1 noncompetitively at an extracellular site without hyperthermia, and that a fragment relieves pain independently of GLP-1 receptor signalling. This generates a falsifiable prediction - analgesia separable from weight loss - and a trial design capable of refuting it.
Key findings
- The first is tissue reversibility, which determines whether disease modification is possible at all: a remodellable vascular substrate responds, an autonomously degenerating parenchyma does not, and a functionally disordered but structurally intact network should.
- The second is molecular access, which determines which agent can work, and it inverts across indications: long-acting human analogues reduce stroke risk while short-acting exendins do not, yet exenatide lowers intracranial pressure in idiopathic intracranial hypertension because the choroid plexus lies outside the blood-brain barrier.
- Chronic migraine occupies the reversible, extra-barrier quadrant.
- Recent receptor-level work shows GLP-1-derived peptides inhibit TRPV1 noncompetitively at an extracellular site without hyperthermia, and that a fragment relieves pain independently of GLP-1 receptor signalling.
- This generates a falsifiable prediction - analgesia separable from weight loss - and a trial design capable of refuting it.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 21 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 13 of the 62 points we could judge it on, which is 21 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Preprints.org) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 13 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 13 of the 62 points we could judge it on is 21 out of 100. |
| Total | 21 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Sulter, G. A. (2026). Reversibility and Access: A Two-Axis Framework for Glucagon-Like Peptide-1 Receptor Agonists Across the Neurological Spectrum, and a Falsifiable Analgesic Hypothesis for Chronic Migraine. Preprints.org. https://doi.org/10.20944/preprints202607.1279.v1
Vancouver
Sulter GA. Reversibility and Access: A Two-Axis Framework for Glucagon-Like Peptide-1 Receptor Agonists Across the Neurological Spectrum, and a Falsifiable Analgesic Hypothesis for Chronic Migraine. Preprints.org. 2026. doi:10.20944/preprints202607.1279.v1.
BibTeX
@article{sulter2026-7e0e4d07,
author = {Sulter, G. A.},
title = {{Reversibility and Access: A Two-Axis Framework for Glucagon-Like Peptide-1 Receptor Agonists Across the Neurological Spectrum, and a Falsifiable Analgesic Hypothesis for Chronic Migraine}},
journal = {Preprints.org},
year = {2026},
doi = {10.20944/preprints202607.1279.v1},
url = {https://doi.org/10.20944/preprints202607.1279.v1}
}
Related studies in Drug development
Also tagged “agonists”
285 studies in the library carry the topic tag “agonists”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 285 tagged studies.